

TRACK RECORD OF THE PUBLIC ISSUES MANAGED BY THE MERCHANT BANKER IN THE LAST 3 FINANCIAL YEARS

Name of the Issue:	Gandhar Oil Refinery (India) Limited			
1. Type of Issue (IPO/FPO)	IPO			
2. Issue Size (Rs. Cr)	INR 500.69 Cr			
3. Grade of issue along with name of the rating agency				
Name	NA			
Grade	NA			
4. Subscription Level (Number of times)	67.89 times (excluding the Anchor Investor Portion) as per the bid books of NSE and BSE (the "Bid Files") after removing multiple and duplicate bids.			

Source: Minutes of the Meeting held for the finalization of the Basis of Allotment dated November 28, 2023

5. QIB Holding (as a % of outstanding capital) as disclosed to stock exchanges

Particulars	Percentage
(i) allotment in the issue	15.42%*
(ii) at the end of the 1st Quarter immediately after the listing of the issue [#]	9.14%
(iii) at the end of 1st FY (March 31, 2024 ^{##}	4.00%
(iv) at the end of 2nd FY (March 31, 2025) [^]	NA
(v) at the end of 3rd FY (March 31, 2026) [^]	NA

(*) As per shareholding pattern as on the date of listing.

(^) QIB Holding not disclosed as reporting for relevant period / fiscal years has not been completed

Source : Shareholding Pattern of the Company for the quarter ended December 31, 2023

Source : Shareholding Pattern of the Company for the quarter ended March 31, 2024.



Consolidated (Rs in Crores) 1st FY (March 31, 2nd FY (March 31, 3rd FY (March 31, Parameters 2024)# 2025)* 2026)* Income from operations 4113.21 N.A. N.A. Net Profit for the period 165.32 N.A. N.A. Paid-up equity share capital 19.57 N.A. N.A. Reserves excluding revaluation reserves 1152.64 N.A. N.A.

6. Financials of the issuer (as per the annual financial results submitted to stock exchanges)

* Financials not disclosed as reporting for the relevant fiscal years has not been completed.

Source : Audited Financial Statements for the year ended March 31, 2024.

7. Trading Status in the scrip of the issuer

Company's Equity Shares are listed on the BSE Limited and the National Stock Exchange of India Limited .

Particulars	Status
(i) at the end of 1st FY (March 31, 2024)	Frequently Traded
(ii) at the end of 2nd FY (March 31, 2025)*	N.A.
(iii) at the end of 3rd FY (March 31, 2026)*	N.A.

* Trading status not disclosed as reporting for the relevant fiscal years has not been completed

8. Change in Directors of issuer from the disclosures in the offer document

Particulars	Name of the Director	Appointed / Resigned
(i) at the end of 1st FY (March 31, 2024)	Nil	Nil
(ii) at the end of 2nd FY (March 31, 2025)*	N.A.	N.A.
(iii) at the end of 3rd FY (March 31, 2026)*	N.A.	N.A.

*Changes in directors not disclosed as reporting for relevant fiscal years has not been completed. There is no change in directors for FY 24-25 till November 15, 2024.



9. Status of implementation of project/ commencement of commercial production

(i) As disclosed in the offer document:

No.	Particulars*	Details of capital expenditure
Silvassa –	Automotive oil unit	
1.	Land acquisition	Not required to be acquired as it is already available
		with the Company.
2.	Civil works	To be completed by March 2024.
		For details see "-Capital expenditure for expansion
		in capacity of automotive oil at our Silvassa Plant" at
		page 131 of Prospectus
3.	Power and electric line	Not required to be acquired as it is already available
		with the Company.
4.	Installation and placement of	Placement of order of plant and machinery by April
	plant and machinery	2024.
		Erection/Commissioning of Plant & Machinery by
		March 2025.
		For details of plant and machinery required to be
		purchased in relation to this proposed capital
		expenditure, see "—Capital expenditure for
		expansion in capacity of automotive oil at our
		Silvassa Plant" at page 131 of Prospectus
5.	Trial production	Not applicable.
6.	Date of commercial	50% by March 2025 and remaining by March 2026.
	production	
7.	Reason for delay (if any)	Not applicable as the capital expenditure is yet to be
		incurred.

(ii) Actual implementation: The implementation of Silvassa – Automotive oil unit is on schedule.

(iii) Reasons for delay in implementation, if any: No Comments

Source : Monitoring Agency Report dated November, 06, 2024 for the quarter ended September, 30, 2024.



10. Status of utilization of issue proceeds

(i) As disclosed in the offer document:

The Company propose to deploy the Net Proceeds towards the Objects in accordance with the estimated schedule of implementation and deployment of funds, as set forth in the table below:

					(in ₹ million)
Sr. No.	Particulars	Total Estimated Cost	Estimated Utilization From	Estimated S Deploy of Net Pro Financial Year	rment
			Net Proceeds	2024	Year 2025
1	Investment into Texol by way of a loan for financing the repayment/pre- payment of a loan facility availed by Texol from the Bank of Baroda	227.13	227.13	227.13	
2	Capital expenditure through purchase of equipment and civil work required for expansion in capacity of automotive oil at the Silvassa Plant	277.29	277.29	277.29	-
3	Funding working capital requirements of the Company	1,850.08	1,850.08	951.39	898.69
4	General corporate purposes	276.53	276.53	276.53	-
5	Net Proceeds	2,631.03	2,631.03	1,732.34	898.69

(ii) Actual utilization:

(in ₹ million)

Sr.	Item Head	Amt.as		Amt. utilized Total			Comments
No.		Proposed in the offer document (in million)	At the beginning of the quarter	During the quarter	At the end of the quarter	Unutilized amt.	of the Monitoring Agency
1	Investment into Texol by way of a loan for financing the repayment/pre- payment of a loan facility availed by Texol from the Bank of Baroda	227.13	227.13	-	227.13	Nil	No comments



2	Capital expenditure through purchase of equipment and civil work required for expansion in capacity of automotive oil at the Silvassa Plant	277.29	64.16	62.85	127.01	150.28	No Comments
3	Funding working capital requirements of the Company	1850.08	1850.08##	Nil	1850.08##	Nil	No comments
4	General corporate purposes	276.53 (#430.08)	395.70	Nil	395.70	35.18	Revision in General Corporate purpose is on account of upward revision in net proceeds by Rs. 154.35 million.
	Total	2785.38	2537.07	62.85	2599.92	185.46	

Revision in General Corporate Purpose is on account of actual issue related expenses being lower than estimated by Rs.154.35 million.

Including Rs.226.00 million paid towards the payment for unsecured loan obtained from the director, which was initially obtained for the purpose of working capital in the month of April, 2024.

The unutilized amt. has been deployed as follows :

Sr. No.	Type of Instrument and name of the entity invested in	Amt. invested (in million)	Return on Investment (%)
1	Fixed Deposit with Indusind Bank	150.0	6.60
2	Balance in public issue account as on 30 th September, 2024	81.62	
3	Balance in monitoring account as on 30 th September, 2024	0.09	
	Total	231.71*	

* includes Rs.46.25 million of unutilized issue related expenses.

(iii) Reasons for deviation, if any: No deviation, The utilization of the issuance of the proceeds is in line with the objects of the Issue.

Source : Monitoring Agency Report dated November, 11, 2024 for the quarter ended September, 30, 2024.



11. Comments of monitoring agency, if applicable

of proceeds of the issue from the objects issua	deviation, The utilization of the ance of the proceeds is in line with objects of the Issue.
---	--

Source : Monitoring Agency Report dated November, 11, 2024 for the quarter ended September, 30, 2024.

12. Pricing Data

Issue Price (Rs.): Designated Stock Exchange: Listing Date: 169 /-**NSE** November 30, 2023

Price parameters	At close of listing day (i.e. At close of 30th calendar		At close of 90th calendar	As at the end of 1st FY after the listing of the issue (March 31, 2024)			
Price parameters Novem	November 30, 2023)	vember 30, day from		Closing price	High (during the FY)	Low (during the FY)	
Market Price on Designated Stock Exchange (NSE)	301.40	272.95	239.25	200.1	344.05	196.40	
NIFTY 50	20,133.15	21731.4	22198.35	22326.90	22526.60	17312.75	
Sectoral Index	NA	NA	NA	NA	NA	NA	

	As at the end of 2nd FY after the listing of the issue (March 31, 2025)*			As at the end of 3rd FY after the listing of the issue (March 31, 2026)*		
Price parameters	Closing price	High (during the FY)	Low (during the FY)	Closing price	High (during the FY)	Low (during the FY)
Market Price on Designated Stock Exchange (NSE)	NA	NA	NA	NA	NA	NA
NIFTY 50	NA	NA	NA	NA	NA	NA
Sectoral Index	NA	NA	NA	NA	NA	NA

Source: NSE website

* Pricing Data not disclosed as reporting for the relevant fiscal years has not been completed



13. Basis for Issue Price (Source of accounting ratios of peer group and industry average may be indicated; Source of the accounting ratios may generally be the same, however in case of different sources, reasons for the same may be indicated)

Accounting ratio		As disclosed in the offer document ⁽¹⁾	At the end of 1st FY (March 31, 2024) ³⁾	At the end of 2nd FY (March 31, 2025) ⁽²⁾	At the end of 3rd FY (March 31, 2026) ⁽²⁾
EPS	Issuer:				
	Consolidated (Basic)	23.77	16.27	N.A	N.A
	Consolidated (Diluted)	23.77	16.27	N.A	N.A
	Peer Group :		-		
	Savita Oil Technologies Limited	Basic – 32.66 Diluted –32.66	Basic – 29.05 Diluted –29.05	N.A	N.A
	Apar Industries Limited	Basic – 166.64 Diluted – 166.64	Basic – 212.10 Diluted – 212.10	N.A	N.A
	Panama Petrochem Limited	Basic – 38.51 Diluted – 38.51	Basic – 32.26 Diluted – 32.26	N.A	N.A
	Galaxy Surfactants Limited	Basic – 107.46 Diluted – 107.46	Basic – 85.03 Diluted – 85.03	N.A	N.A
	Privi Speciality Chemicals Limited	Basic – 5.45 Diluted – 5.45	Basic – 24.43 Diluted – 24.43	N.A	N.A
	Rossari Biotech Limited	Basic – 19.46 Diluted – 19.38	Basic – 23.67 Diluted – 23.62	N.A	N.A
	Fairchem Organics Limited	Basic – 33.41 Diluted – 33.41	Basic – 31.10 Diluted – 31.10	N.A	N.A
	Industry Avg:	NA	N.A	N.A	N.A
P/E	Issuer:				



Consolidated (Basic)	7.11	12.30	N.A	N.A
Peer Group ⁽				
Savita Oil Technologies Limited	10.04	15.85	N.A	N.A
Apar Industries Limited	33.65	32.94	N.A	N.A
Panama Petrochem Limited	8.07	10.26	N.A	N.A
Galaxy Surfactants Limited	26.21	26.69	N.A	N.A
Privi Speciality Chemicals Limited	233.28	40.55	N.A	N.A
Rossari Biotech Limited	36.74	28.49	N.A	N.A
Fairchem Organics Limited	35.31	38.17	N.A	N.A
Industry Composite:	54.77	N.A	N.A	N.A
Issuer:	-	-		
Consolidated	32.28%	14.10%	N.A	N.A
Peer Group:				
Savita Oil Technologies Limited	16.68%	12.38%	N.A	N.A
Apar Industries Limited	32.28%	21.29%	N.A	N.A
Panama Petrochem Limited	27.08%	17.70%	N.A	N.A
Galaxy Surfactants Limited	22.04%	13.83%	N.A	N.A
Privi Speciality Chemicals Limited	2.57%	10.32%	N.A	N.A
Rossari Biotech Limited	12.47%	12.47%	N.A	N.A
	(Basic)Peer Group(Savita Oil Technologies LimitedApar Industries LimitedPanama Petrochem LimitedGalaxy Surfactants LimitedPrivi Speciality Chemicals LimitedRossari Biotech LimitedFairchem Organics LimitedIndustry Composite:Issuer:ConsolidatedPeer Group:Savita Oil Technologies LimitedPanama Petrochem LimitedPrivi Speciality Composite:Industry Composite:Privi SpecialitatedPeer Group:Savita Oil Technologies LimitedPeer Group:Panama Petrochem LimitedPanama Petrochem LimitedPanama Petrochem LimitedRossari BiotechSavita Oil Technologies LimitedPanama Petrochem LimitedRossari BiotechRossari Biotech	(Basic)Peer Group(Savita Oil Technologies10.04Limited10.04Apar Industries Limited33.65Panama Petrochem Limited8.07Galaxy Surfactants Limited26.21Privi Speciality Chemicals Limited233.28Rossari Biotech Limited36.74Industry Composite:35.31Industry Composite:Consolidated32.28%Peer Group:Savita Oil Technologies Limited16.68%Panama Petrochem Limited32.28%Panama Petrochem Limited27.08%Panama Petrochem Limited22.04%Privi Speciality Chemicals Limited2.57%	(Basic)12.30Peer Group ¹ Savita Oil Technologies10.04Inited10.04Apar Industries33.65Limited33.65Apar Industries33.65Limited8.07Panama Petrochem Limited8.07Panama Petrochem Limited26.21Galaxy Surfactants Limited26.21Calaxy Surfactants Limited233.28A0.55Rossari Biotech Limited36.74Industry Composite:54.77N.AIssuer:Consolidated32.28%14.10%Peer Group:Savita Oil Technologies16.68%Apar Industries Limited32.28%Apar Industries LimitedSavita Oil Technologies16.68%12.38%Panama Petrochem Limited27.08%Privi Speciality Chemicals Limited22.04%Panama Petrochem Limited22.04%Panama Petrochem Limited22.04%Pivi Speciality Chemicals Limited2.57%Privi Speciality Chemicals Limited12.47%	(Basic)12.30N.APeer Group ⁽ Savita Oil Technologies10.0415.85N.AApar Industries33.6532.94N.APanama Petrochem Limited8.0710.26N.AGalaxy Surfactants Limited26.2126.69N.AGalaxy Surfactants Limited233.2840.55N.ARossari Biotech Limited36.7428.49N.AFairchem Organics Limited35.3138.17N.AIndustry Composite:54.77N.AN.AIssuer:Consolidated32.28%14.10%N.APeer Group:Cansolidated32.28%21.29%N.APanama Petrochem Limited27.08%17.70%N.APanama Petrochem Limited22.04%13.83%N.APrivi Speciality Chemicals Limited22.04%13.43%N.APanama Petrochem Limited27.08%17.70%N.ARossari Biotech12.47%10.32%N.A



	Fairchem Organics Limited	17.70%	13.97%	N.A	N.A
	Industry Composite:	NA	N.A	N.A	N.A
NAV	Issuer:				
	Consolidated	95.03	119.80	N.A	N.A
	Peer Group:			-	
	Savita Oil Technologies Limited	209.7	234.69	N.A	N.A
	Apar Industries Limited	584.39	965.01	N.A	N.A
	Panama Petrochem Limited	157.39	182.27	N.A	N.A
	Galaxy Surfactants Limited	530.97	614.74	N.A	N.A
	Privi Speciality Chemicals Limited	213.88	236.66	N.A	N.A
	Rossari Biotech Limited	165.92	189.63	N.A	N.A
	Fairchem Organics Limited	199.11	222.68	N.A	N.A
	Industry Avg:	NA	N.A	N.A	N.A

Notes:

(1) Prospectus dated November 25, 2023.

- (2) Not disclosed as the reporting for the relevant fiscal years has not been completed.
- (3) Source : Audited Financial Statements for the financial year 2023-24.

14. Any other material information

Particulars	Date
The Company has informed about the receipt of work order worth of Rs. 17,41,49,250 (Rupees Seventeen Crore Forty-One lakhs Forty-Nine thousand Two Hundred and Fifty only) from Ajmer Vidyut Vitran Nigam Limited for the purpose of supply of EHV Grade Type-II Transformer Oil.	22-03-2024
The Company has informed about the receipt of work order worth of Rs. 15,20,43,000 (Rupees fifteen crore twenty lakhs forty-three thousand only) from BESCOM for the purpose of supply of New Insulating Oil Uninhibited (U) Type-II Transformer Oil.	02-04-2024



The Company has informed about the following abanges:	22.05.2024
The Company has informed about the following changes :	22-05-2024
1) Appointment of M/s. G. D. Singhvi & Co., Chartered Accountants, (Firm	
registration No.110287W) Mumbai as an Internal Auditors of the Company for the Financial Year 2024-25.	
2) Appointment of M/s. Maulin Shah & Associates, Cost accountant, as	
Cost Auditor of the Company for the Financial Year 2024-25.	
3) Appointment of M/s. Manish Ghia & Associates, Practicing Company	
Secretaries, as Secretarial Auditors of the Company for the Financial Year 2024-25	
The Company has informed exchange regarding –	30-05-2024
1. Show Cause Notice has been issued by GST Authority for the period	
April 2019 to March 2020 proposing tax demand of Rs. 47.16 crores	
along with applicable interest and penalty in the matter of tax liability	
under reverse charge basis on certain services.2. Show Cause Notice has been issued by GST Authority for the period	
April 2019 to March 2020 proposing tax demand of Rs. 1.23 crores	
along with applicable interest and penalty in the matter of tax liability	
under reverse charge basis on certain services	
The Company has informed exchange regarding – Show Cause Notice issued by GST Authority for the period April 2019 to March 2020 proposing tax demand	31-05-2024
of Rs. 4.95 crores and additionally applicable interest and penalty in the matter	
of difference in Input Tax Credit Availed.	
The Company has informed exchange regarding the Change of Corporate	28-06-2024
Identification Number (CIN) of the Company from 'U23200MH1992PLC068905'	
to L23200MH1992PLC068905'and status has been changed from "Unlisted" to "Listed" pursuant to the listing of equity shares of the Company on BSE Limited	
('BSE') and National Stock Exchange of India Limited ('NSE').	
The Company has informed exchange about order issued by the Office of the	28-06-2024
Commissioner of Customs (Adjudication), Mumbai proposing to impose penalty	
of Rs. 1,20,00,000/- and redemption fine of Rs. 6,00,00,000/- and further demand of IGST amount of Rs. 30,44,44,827/- and an Interest amount of Rs.	
18,08,76,842/- which has already been paid by the Company.	
The Company further informed that they have already paid the IGST amount as	
well as Interest amount as stated above and is in process of filing appropriate appeal against the said Order within the prescribed timelines before the relevant	
Adjudicating Authority.	
The Company has informed the exchange about the receipt of order from the	01-07-2024
Abu Dhabi National Oil Company to its Foreign Material subsidiary namely Texol	
Lubritech FZC for Manufacture, package, label and make available the Products for Adnoc Distribution on contract basis for a period of 3 years.	
for Autoc Distribution on contract basis for a period of 5 years.	
The Company further informed that the estimated annual value of contract is	
USD 45 million equivalent to approx. INR 375 Crores, for each year 2024, 2025	
and 2026. The Company has informed about the board approval for incorporation of a	25-07-2024
wholly owned subsidiary Private Limited company in India under the name and	25-07-2024
style "Gandhar Lifesciences Private Limited" with Rs. 1,00,00,000/- (1 crore) as	
paid up capital for manufacturing Pharma, cosmetic and other related products.	
The Company has informed about the receipt of an order from the Joint	23-08-2024
Commissioner, Central GST & Central Excise, Daman Commissionerate for tax demand of aprox Rs. 4.95 crores and additionally applicable interest and penalty	
in the matter of difference in Input Tax Credit availed for FY 2019-20.	
The Company further informed that they will be filing appropriate appeal to the	
said Order within the prescribed timelines before the Adjudicating Authority. The Company has informed about the resignation of Mr. Natesh P., Sr. General	30-08-2024
Manager, at Taloja Plant and Senior Management Personnel (SMP) of the	
Company w.e.f. close of business hours on 30th September, 2024.	



The Company has informed about the inspection carried out by the United States Food & Drug Administration (USFDA) of Company's manufacturing facility located at Taloja. The Company further informed that on conclusion of inspection, Company has received 2 (Two) observations in Form 483.

06-11-2024

Source- Stock Exchange Filings

All the above information has been updated till November 15, 2024, unless indicated otherwise.